文章：

基底细胞癌：一位多面性的老友

Basal Cell Carcinoma: An Old Friend with Multiple Faces

原文发布日期：15 March 2025

DOI: 10.3390/cancers17060993

类型: Article

开放获取: 是

英文摘要：

BCC is the most prevalent form of skin cancer, characterized by diverse clinical and pathological subtypes ranging from indolent to highly aggressive forms. While the majority of BCC cases are treated effectively with surgery or local therapies, locally advanced BCC (laBCC) and metastatic BCC (mBCC) pose significant therapeutic challenges. Recent advances in HHIs and immunotherapy have transformed the treatment landscape in such cases. However, resistance and intolerance to these treatments necessitate alternative approaches, including chemotherapy. Platinum-based agents such as cisplatin and carboplatin have shown limited efficacy but remain viable options in rapidly progressive cases. Among the therapeutic innovations to be explored, further lines of immunotherapy as well as combination therapies involving immunotherapy and targeted therapy have been proposed. This review synthesizes the current understanding about BCC subtypes, risk stratification, and emerging treatments, with a particular focus on laBCC and mBCC.

摘要翻译： 

基底细胞癌（BCC）是最常见的皮肤癌类型，其临床与病理亚型多样，涵盖从惰性到高度侵袭性的多种表现形式。虽然大多数BCC病例可通过手术或局部治疗有效控制，但局部晚期BCC（laBCC）和转移性BCC（mBCC）仍构成显著治疗挑战。近年来，Hedgehog通路抑制剂（HHIs）与免疫疗法的进展为此类病例的治疗格局带来了变革。然而，针对这些治疗的耐药性和不耐受现象使得包括化疗在内的替代方案成为必要。以顺铂和卡铂为代表的铂类药物虽疗效有限，但在快速进展病例中仍是可行选择。在有待探索的治疗创新中，后续免疫治疗线以及免疫治疗与靶向治疗的联合方案已被提出。本综述整合了当前对BCC亚型分类、风险分层及新兴疗法的认识，并特别聚焦于laBCC与mBCC的治疗进展。

原文链接：

Basal Cell Carcinoma: An Old Friend with Multiple Faces